Six months of Kaftrio (elexacaftor-tezacaftor-ivacaftor), which is marketed as Trikafta in the U.S., led to marked reductions in abdominal symptoms among people with cystic fibrosis (CF), a study in Germany and the U.K. found. “To our knowledge, this is the first study assessing gastrointestinal symptoms, with a validated…
One year of Trikafta treatment for adults with cystic fibrosis (CF) post-lung transplant resulted in only limited improvements in sinus and digestive problems and was not well-tolerated, a small study found. In fact, among the 13 patients in the study, the discontinuation rate for the triple-combination therapy was 38.4%.
Kaftrio, a triple combination of elexacaftor, tezacaftor, and ivacaftor sold as Trikafta in the U.S., may ease acid reflux and symptoms of nasal and sinus cavity infection in cystic fibrosis (CF) patients with advanced lung disease, a U.K.-based study found. The study, “Elexacaftor-tezacaftor-ivacaftor improve gastro-oesophageal reflux and…
Taking so-called CFTR modulators — medications to correct the disease-causing faulty CFTR protein in cystic fibrosis (CF) — may significantly reduce a patient’s risk of severe COVID-19, according to a study by an international team of researchers. In fact, non-lung transplant CF patients in the U.S. and the U.K. using…
Two patients have been dosed in a clinical trial testing BX004, a nebulized phage therapy designed to kill Pseudomonas aeruginosa, the most common cause of lung infections in people with cystic fibrosis (CF). The Phase 1b/2a trial (NCT05010577), which is funded by the Cystic Fibrosis Foundation and underway in…
The prevalence of cystic fibrosis (CF), used as an indicator of the number of CF carriers, was correlated with rates of COVID-19 and related mortality during the pandemic’s early stages across 37 different countries, a study showed. “This report suggests a possible contribution of the CFTR genetic profile of…
More frequent lung function tests in young people with cystic fibrosis (CF) markedly increased the diagnoses of pulmonary exacerbations — bouts of lung symptom worsening — leading to improved treatment and better lung function, a Brazilian study suggested. “The impact of such a simple initiative can be substantial and…
Treatment with the probiotic Vivomixx appeared to lead to healthful changes in the gut microbiome of cystic fibrosis (CF) patients in a small clinical trial, including six with CF-related…
A newly launched biotech company called Carbon Biosciences is aiming to develop lung-specific gene therapy vectors — vehicles to deliver genetic material directly into a cell — to help treat cystic fibrosis (CF). The company has $38 million in series A financing, funded in part by the Cystic…
Regular use of antibiotics to treat persistent infections is linked with hypersensitivity reactions in individuals with cystic fibrosis (CF), a new study has found. Specifically, “the risk is highly associated with the number of cumulative exposures to antibiotics and increasing age,” the researchers wrote. And intravenous, or into-the-vein, administration…
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Get regular updates to your inbox.